Debiopharm Group ( Debiopharm Group)

Primary tabs

Debiopharm Group's picture

Management

Contact Address

About Debiopharm Group

Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs.

Debiopharm Group press release, blog etc

Wed, 03/12/2025 - 06:21 Debiopharm mutualise son infrastructure de bornes de recharges pour les taxis electriques ou hybrides de Lausanne
Tue, 02/25/2025 - 18:45 MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy in Advanced Breast Cancer
Mon, 02/03/2025 - 06:03 Lancement de la 10e edition du Challenge Qualite de Vie du Patient
Wed, 01/29/2025 - 17:39 Genialis advances biomarker discovery to reduce risk in cancer drug development targeting DNA damage response pathways
Tue, 01/14/2025 - 18:49 Swiss-based non-profit GARDP supports the development of Debiopharms new potential treatment for gonorrhoea
Tue, 08/27/2024 - 13:57 Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference
Sun, 12/11/2022 - 22:45 Le 7e Challenge Qualite de vie du patient recompense le dispositif de massage MRM destine aux personnes en fauteuil roulant, aux personnes agees et aux sportifs et qui ameliore la circulation sanguine et lymphatique et la reeducation physique
Wed, 11/09/2022 - 15:13 Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data
Mon, 10/03/2022 - 11:36 Debiopharm reinforces the bond between Swiss and Japanese cancer research with the 2022 JCA-Mauvernay Award Ceremony
Thu, 09/22/2022 - 11:02 Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology
Tue, 09/13/2022 - 18:52 Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Wed, 09/07/2022 - 10:37 One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress
Sun, 07/24/2022 - 21:14 Debiopharms new agreement with the University of Geneva boosts scientific Innovation Hub in the Lemanic region of Switzerland through the IDEAL initiative
Mon, 07/11/2022 - 10:06 Paul Scherrer Institute regains License from Debiopharm for the Development of Tageted Radiopharmaceutical Debio 1124
Mon, 05/09/2022 - 00:14 Debiopharm leads investment round for evidence-based digital cancer therapeutic app Mika to empower cancer patients
Wed, 03/30/2022 - 15:01 VivoSense Announces Closing of $25M Series A Financing Round Co-led by Xontogeny and Debiopharm
Mon, 02/07/2022 - 22:38 Challenge pour la Qualite de vie du patient 2022 : lappel a projets est ouvert !
Sun, 01/09/2022 - 18:28 Debiopharm invests in VeriSIM Lifes $15m series A round to advance AI-enabled drug research
more

InfoBox

HomePagewww.debiopharm.com
Facebookwww.facebook.com/pages/Debiopharm-Group/180425588695192
Twittertwitter.com/DebiopharmNews
YouTubewww.youtube.com/user/DebiopharmTV
LinkedInwww.linkedin.com/company/32979?trk=tyah
Wikipediaen.wikipedia.org/wiki/Debiopharm